KalVista Pharmaceuticals, Inc.

Throughout #WomensHistoryMonth, we celebrate the incredible women of #TeamKalVista and beyond who are making breakthroughs in science, healthcare, and patient advocacy. From pioneering researchers like Dr. Virginia Donaldson, who first identified the cause of #HAE in 1963, to today’s trailblazers working tirelessly for better patient outcomes, their contributions shape the future of medicine. We honor them—and women everywhere—for their unending dedication, limitless potential, and immeasurable impact.

Yesterday, we shared key insights into our vision for the future of #HAE treatment. Watch our Commercial Day webcast to learn how we’re preparing for our first potential commercial launch and stay tuned for what’s next: https://bit.ly/424L3Su.

Excitement is growing in the #HAE community for our investigational oral on-demand treatment. We’re pleased to announce early completion of enrollment in the KONFIDENT-KID clinical trial in pediatric patients aged 2 to 11. Learn more: https://bit.ly/4j4xIQY.

KalVista was honored to sponsor the HAE International (HAEi) Regional Conference Asia-Pacific, where patients, caregivers, healthcare experts, and the pharmaceutical industry come together to drive advancements in #HAE care. More than just a gathering—the HAEi Regional Conference is a testament to the strength, resilience, and unity of the HAE community. Our team is deeply committed to patient-centricity and we’re proud to support this event where voices are heard, experiences are shared, and progress is made. Thank you to HAEi for having us!

Investors and analysts: Join us virtually for a Commercial Day on March 25! You’re invited to learn about our vision for the future of KalVista, including the commercialization strategy, plans, and progress for our investigational treatment for #HAE. Register today: https://bit.ly/43S73ST.

This past quarter showed meaningful progress for #TeamKalVista, building momentum ahead of a milestone year: - Announced seventh regulatory application submission and secured orphan drug designation in Japan for #HAE -Presented new data that showed the potential of our investigational medicine to address critical unmet needs in laryngeal attacks, adolescents with HAE and patients experiencing attacks despite long-term prophylaxis -Will host virtual investor day on March 25th to discuss commercialization strategy ahead of June PDUFA Read more about our progress: https://bit.ly/4kDgH1I.

Managing #HAE attacks can be particularly challenging for adolescents. Currently, all on-demand treatments approved in the U.S. are administered via injection, which can be painful and anxiety-inducing, often resulting in delays in treatment. At #AAAAI2025, we revealed new data highlighting the burden young people living with HAE face and the urgent need for alternatives: https://bit.ly/3R6vapD.

Thank you to MassBio for hosting such an insightful and inspiring #RareDiseaseDay Forum! Hearing patients, caregivers, and researchers advocate for advancements in rare disease care left #TeamKalVista energized for the future of HAE.

We’re here at the 2025 American Academy of Allergy, Asthma and Immunology - AAAAI / WAO Joint Congress—are you? Meet #TeamKalVista at booth #1016 and don’t miss Saturday’s symposium, “Closing Gaps in HAE Management: Understanding What Control Means for Your HAE Patients,” led by Dr. Marc Riedl, Dr. Paula Busse, and Dr. Michael Manning. #AAAAI2025

#HAE can be challenging to diagnose, with symptoms that vary from patient to patient. Look out for the possible signs of HAE—like tightness, pressure, swelling, and pain.